作者: Françoise Aubrit , Fabien Perugi , Arnaud Léon , Fabienne Guéhenneux , Patrick Champion-Arnaud
DOI: 10.1016/J.VACCINE.2015.06.110
关键词: Cell 、 Business 、 Vaccine Production 、 Cell culture 、 Chikungunya 、 Cell substrate 、 Production (economics) 、 Virology 、 Viral Vaccine 、 Pandemic 、 Public Health, Environmental and Occupational Health 、 General Immunology and Microbiology 、 Molecular medicine 、 General Veterinary 、 Infectious Diseases
摘要: Vaccines have been used for centuries to protect people and animals against infectious diseases. For vaccine production, it has become evident that cell culture technology can be considered as a key milestone the result of decades progress. The development implementation substrates permitted massive safe production viral vaccines. demand in new vaccines emerging diseases, increasing volumes, stringent safety rules manufacturing made mandatory producer factories. In this review, we focus on human Depending nature vaccine, choice substrate is critical. Each manufacturer intending develop candidate should assess several during early phase order select most convenient application. First, quite naturally central concern Regulatory Agencies, answer regulatory stringency. addition, competitive terms viral-specific yields costs. No substrate, even so-called "designer" lines, able fulfil all requested criteria Therefore, availability variety essential because improves chance successfully respond current future needs linked or re-emerging diseases (e.g. pandemic flu, Ebola, Chikungunya outbreaks).